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Abstract
Growing evidence suggests that long non‐coding RNAs NORAD and miR‐205 play 
a significant role in regulating cancer progression and metastasis. In this study, high 
expression of NORAD was firstly observed in melanoma tissues and human malig-
nant melanoma cell lines, our aim was to study the interaction of them in the process 
of invasion and migration of malignant melanoma cells. NORAD, miR‐205, and 
EGLN2 mRNA level in MM cells was detected by qRT‐PCR. In situ hybridization 
(ISH) was performed to detect NORAD expression in MM tissues specimens. Effects 
of NORAD and miR‐205 on Prolyl hydroxylase 2 (EGLN2) expression was explored 
by western blot in MM cells line. Dual‐luciferase reporter assay was performed to 
verify the interaction relationship between NORAD and miR‐205, as well as, 
miR‐205 and EGLN2. Transwell assay was conducted to explore the effects of 
NORAD and miR‐205 in vitro. Xenografts in nude mice experiment were used to 
confirm the role of NORAD and miR‐205 in vivo. In vitro, NORAD knockdown 
significantly inhibited migration and invasion of malignant melanoma cells and ele-
vated the expression of miR‐205, there was an interaction between miR‐205 and 
NORAD in the RNA‐induced silencing complex. Upregulation of miR‐205 induced 
significant inhibition of migratory and invasive ability compared with the scrambled 
control. However, downregulating NORAD largely reversed this effect. Furthermore, 
the regulatory effects of miR‐205 on EGLN2 levels and the induction of endoplasmic 
reticulum stress were reversed by NORAD. In vivo, deletion of miR‐205 induced 
tumor growth in nude mice. NORAD may play critical roles in tumorigenesis and 
progression of malignant melanoma by regulating of the miR‐205‐EGLN2 pathway, 
and may serve as a new therapeutic target.
K E Y W O R D S
long non‐coding RNA, melanoma, microRNA, oncogene
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1 |  INTRODUCTION
Malignant melanoma (MM) is an aggressive skin cancer that 
accounts for 78% of skin cancer‐associated deaths.1,2 The in-
cidence of MM is increased by approximately 3% annually all 
over the world.3 Although significant advances have been ob-
tained in diagnosis and treatments of MM, the prognosis of MM 
remains too poor and it still causes nearly 50 000 deaths per year 
worldwide.4 Therefore a better understanding of the underlying 
molecular mechanism of melanoma is important to develop ad-
juvant or alternative therapies and improve treatment efficacy.
Long non‐coding RNAs (lncRNAs) are non‐protein‐cod-
ing RNAs comprised of over 200 nucleotides. They are im-
portant for various cellular processes, such as cell growth, 
cycle progression, invasion, and metastasis.5,6 In addition, 
growing evidence suggests that some lncRNAs can promote 
or suppress tumor growth in MM.7 For example, lncRNA 
MALAT1 (metastasis‐related lung adenocarcinoma tran-
script 1) is upregulated in uveal melanoma tissues and cells, 
and silencing of MALAT1 suppresses uveal melanoma cell 
proliferation, colony information, invasion, and migration.8 
The long non‐coding RNA growth arrest‐specific transcript 
5 (GAS5) has an anticancer function in melanoma via the 
mediation of gelatinase A and B activities.9
The non‐coding RNA activated by DNA damage 
(NORAD), also known as LINC00657, is located at 20q11.23. 
NORAD is highly conserved, it maintains genomic stability 
by repressing the stability and translation of mRNAs seques-
tering the PUMILIO protein.10 Previously, we reported that 
NORAD can act as a promoter of cellular stress responses 
in melanocytes.11 Moreover, NORAD knockdown suppresses 
the growth and proliferation of breast cancer cells, suggesting 
that NORAD may play an oncogenic role in breast cancer.12 
However, the functions of NORAD in MM are still unknown.
Presently, we demonstrated the elevated expression of 
NORAD in MM tissues and cells. We also examined the ef-
fects and underlying mechanisms of NORAD expression in 
melanoma cells. Our findings clarify the significance of ln-
cRNAs in MM and may provide an additional insight into the 
role of NORAD in the progression of MM.
2 |  MATERIALS AND METHODS
2.1 | Cell transfection
Including paraffin‐embedded primary MM (62 cases), and 
normal skin tissues (20 cases) was purchased from Auragene 
Co. Ltd (cat No. TC0229; Changsha, China) for in situ hy-
bridization confirmation of NORAD expression. Human 
melanocytes (HM) and four human MM cell lines (A375, 
WM451, SK‐MEL‐24, and WM35) purchased from the 
American Type Culture Collection (Manassas, VA) were 
cultured in RPMI‐1640 medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Gibco, Carlsbad, 
CA) in a humidified atmosphere of 5% CO2 at 37°C. Ectopic 
miR‐205 expression was observed after transfection with ei-
ther pre‐miR‐205 or anti‐miR‐205 (Genepharma, Shanghai, 
China) using Lipofectamine 3000 (Invitrogen). Knockdown 
of NORAD was performed using lentivirus (Lv) containing 
short hairpin (sh)RNA sequences of NORAD (GeneCopoecia, 
Guangzhou, China). Cells were cultured in either 6‐well clus-
ters or 96‐well plates for 24 or 48 hours, and then used to 
experiments or RNA/protein extraction.
2.2 | In situ hybridization (ISH)
The ISH was performed to detect NORAD expression in tis-
sues specimens using digoxin‐labeled probe designed and syn-
thesized by Sangon Biotech Co. Ltd. (Shanghai, China). The 
NORAD probe was TCTACTTCTGTCATACATTGGC) . The 
Enhanced Sensitive ISH Detection kit I (catalog no. MK1030; 
Wuhan Boster Biological Technology Ltd., Wuhan, China) was 
used to process the sample slices according to the manufactur-
er's protocol. The slides were then treated using 3, 3′‐diamin-
obenzidine (DAB; Fuzhou Maixin Biotech Co. Ltd., Fuzhou, 
China) for 5 minutes and counterstained with hematoxylin 
for 90s. At last, the slides were mounted and dried. Images of 
slides were captured with a model BX51 microscope (Olympus 
Corporation, Tokyo, Japan) at a magnification of 200× or 400×.
2.3 | Quantitative real‐time reverse 
transcription PCR (qRT‐PCR)
Total RNA was extracted using Trizol reagent (Invitrogen). 
Mature miR‐205 expression was detected using a Hairpin‐
it™ miRNA qRT‐PCR kit (Genepharma, Shanghai, China) 
in line with the manufacturer's instructions. Expression 
of RNU6B served as an endogenous control. NORAD ex-
pression was measured using the SYBR green qRT‐PCR 
assay (Takara Bio, Dalian, China). Expression of β‐actin 
was used as an endogenous control. The primers used were: 
NORAD, sense, CCTGGAAGGTGAGCGAAGT, anti‐ 
sense, AGAGGGTGGTGGGCATTT; and β‐actin, sense, 
AGGGGCCGGACTCGTCATACT, anti‐sense, GGCGGC 
ACCACCATGTACCCT. qRT‐PCR was performed at 95.0°C 
for 3 minutes, followed by 39 circles at 95.0°C for 10 sec-
onds and 60°C for 30 seconds. Data were analyzed using the 
2−ΔΔCT method.
2.4 | Transwell assay
Tumor cell invasion and migration capacities were assessed 
using Transwell inserts with 8 μm pores (Corning, NY). To 
assess invasion capacity, after transfection for 24 hours, cells 
(3.0 × 105) cultured in serum‐free medium were added to the 
apical chamber that was pre‐coated with Matrigel matrix (BD, 
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Franklin Lakes, NJ). FBS (10%, 500 μl) was dispensed in the 
matching basolateral chamber. After incubation for 48 hours, 
non‐invading cells that remained on the upper chamber surface 
of the transwell membrane were removed using a cotton swab. 
Invading cells that had traversed the membrane were fixed with 
methanol and stained with 0.1% crystal violet. Images were ob-
tained and the cells were enumerated. The migration assay was 
performed the same way, except that 2 × 105 cells were added 
into the chambers without a pre‐coated matrix gel. Six fields at 
100× magnification were randomly selected and the cells were 
counted. Each experiment was conducted three times.
2.5 | Western blot analysis
The expressions of EGLN2, glucose‐regulated protein 78 
(GRP78), enhancer‐binding protein homologous protein 
(CHOP), eukaryotic elongation factor 2 kinase alpha (eIF2α), 
and phospho‐eIF2α (p‐eIF2α) in MM cell lines were deter-
mined by western blot analysis. The cells were lysed by RIPA 
buffer with 1 phenylethylsulfonyl fluoride. The proteins were 
separated using minigel SDS‐PAGE and transferred to a poly-
vinylidene fluoride membrane. After incubation with primary 
antibody (anti‐EGLN2, anti‐GRP78, anti‐CHOP, eIF2α, and 
anti‐p‐eIF2α; all from ImmunoWay Biotechnology Company, 
Plano, TX; anti‐β‐actin from Abcam, Cambridge, UK) at 4°C 
overnight, blots were incubated with horseradish peroxidase‐
labeled secondary antibody (1:5000, Auragene, Changsha, 
China). Signals were developed by enhanced chemilumines-
cence (Millipore, Billerica, MA). β‐actin was used as the en-
dogenous protein for normalization.
2.6 | Dual‐luciferase reporter assay
NORAD (NCBI Reference Sequence: NR_027451.1) 
and the 3′UTR of EGLN2 (NCBI Reference Sequence: 
NM_053046.3) containing a putative miR‐205 binding site 
were synthesized by General Biosystem Co, Ltd. (Anhui, 
China). The qRT‐PCR products were subcloned and incor-
porated in a psiCHECK‐2 vector (Promega, Madison, WI). 
A psiCHECK‐2 construct with NORAD or 3′UTR EGLN2 
with a mutant seed sequence was done to verify the con-




Luciferase activity was tested using a dual‐luciferase re-
porter assay system (Promega) normalized to Renilla lucif-
erase activity.
2.7 | RNA immunoprecipitation (RIP)
RIP experiments were conducted using a Magna RIP RNA‐
Binding Protein IP Kit (Millipore) together with Ago2 
antibody (Cell Signaling, Danvers, MA) as described by the 
manufacturers. Purified RNAs in the precipitates were used 
to determine NORAD and miR‐205 expression.
2.8 | Xenografts in nude mice
All animal experiments complied with the NIH Animal Care 
Guidelines, and all experiments were approved by the Ethics 
Committee of the Faculty of Experimental Animals, Central 
South University, Changsha, China. Male BALB/c‐nu/nu 
(4‐6‐weeks of age raised in the animal laboratory of the Third 
Xiangya Hospital, Central South University) were kept in 
specific pathogen‐free conditions. Six nude mice were sub-
cutaneously injected in the ventral trunk with 2 × 106 cells 
in 200 μL Dulbecco's modified Eagle's medium. Tumor vol-
ume was calculated as V (mm3) = 0.5 × a × b2, where a is 
the maximum length to diameter and b is the maximum trans-
verse diameter. Nude mice were sacrificed to assay the tumor 
volume and weight 35 days after tumor implantation.
2.9 | Statistical analyses
SPSS 17.0 statistical software (SPSS Inc., Chicago, IL) was 
used. All measurement data are expressed as mean ± SD. 
The difference between the two groups was estimated by 
Student's t‐test, and difference among multiple groups was 
analyzed by one‐way ANOVA. A value of P < 0.05 was con-
sidered statistically significant.
3 |  RESULTS
3.1 | NORAD is upregulated in melanoma 
tissues and cell lines
ISH and qRT‐PCR assays were used to detect NORAD level in 
melanoma tissues and normal tissues. ISH revealed higher ex-
pression of NORAD in MM tissues (62 cases) compared to nor-
mal tissues (20 cases) (Figure 1A and B). qRT‐PCR confirmed 
NORAD upregulation in melanoma tissues compared to nor-
mal tissues (Figure 1C). The expression of NORAD in human 
melanocyte and MM human cell lines (A375, WM451, SK‐
MEL‐24, and WM35) were also measured. An obviously up-
regulation of NORAD in the melanoma cell lines was observed 
comparing with the control human melanocytes (Figure 1D), 
which implicated the upregulation of NORAD in MM.
3.2 | Downregulation of NORAD inhibits 
MM cell migration and invasion
To assess whether NORAD affects the malignant behavior 
of A375 and WM35 cells or not, NORAD knockdown cells 
were constructed (Figure 2A). Next, we examined the in-
fluence of NORAD on migration and invasion capacities of 
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F I G U R E  1  NORAD is frequently downregulated in MM tissues and cell lines. (A) ISH was performed to detect the expression of NORAD 
in MM tissues and normal skin tissues. (B) IPP6.0 software was used to analyzed the results of the ISH assay for NORAD expression. (C) The 
expression of NORAD in MM tissues was measured by qRT‐PCR. (D) qRT‐PCR was also used to detect the expression of NORAD in MM cell 
lines and normal human melanocytes (HM). *P < 0.05, **P < 0.01, ***P < 0.001 vs normal control (NC)
F I G U R E  2  Downregulation of 
NORAD inhibits the migration and invasion 
of malignant melanoma cells. (A) qPCR 
was performed to detect the expression of 
NORAD in A357 and WM35 cells after 
transfection with Lv‐shNORAD. Cells 
treated with Lv‐shNC were used as control. 
(B) NORAD knockdown inhibited the 
migration of A357 and WM35 cells. (C) 
NORAD knockdown inhibited the invasion 
of A357 and WM35 cells. **P < 0.01, 
***P < 0.001 vs normal control (NC) 
group. Images were obtained at 100× 
magnification
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MM cells. As shown in Figure 2B and C, NORAD knock-
down restrained migration by approximately 70% in A375 
cells and by nearly 60% in WM35 cells. A similar finding 
was observed for cell invasion; A375 and WM35 cell inva-
sion was significantly inhibited compared with the normal 
control group (P < 0.05).
3.3 | MiR‐205 is a target of NORAD in 
MM cells
Bioinformatics analysis (StarBase, http://starbase.sysu.
edu.cn/browseNcRNA.php) predicted 67 potential targeted 
miRNAs of NORAD. Of these, miR‐205, miR‐17, miR‐
25‐3p, miR‐93‐5p, and miR‐106b‐5p were closely related to 
melanoma cellular endoplasmic reticulum (ER) stress. The 
miR‐205 binding site was found in the NORAD transcript 
(Figure 3A). After detecting the expression levels of the five 
aforementioned miRNAs in melanoma tissue, only miR‐205 
was significantly negatively correlated with NORAD 
(Figure 3B). An RNA pull‐down experiment was done to de-
termine whether the presence of both miR‐205 and NORAD 
in RNA‐induced silencing complex (RISC). Both miR‐205 
and NORAD were found in the Ago2 pellet in A375 and 
WM35 cells, knockdown of NORAD elevated the expression 
of miR‐205 (Figure 3C and D).
To further study if the NORAD is directly targeted 
miR‐205, the transcript of NORAD was cloned down-
stream to wild‐type (wt)‐NORAD and a mutant version 
of NORAD (mut‐NORAD) was also constructed through 
binding site mutagenesis. The luciferase activity of the 
cells was decreased with compared to scramble control 
cells. Furthermore, the putative binding site of the mutant 
F I G U R E  3  MiR‐205 is a target of 
NORAD in malignant melanoma cells. (A) 
Schematic illustration of miR‐205 putative 
target sites in the transcript of NORAD. 
(B) Correlation between the expression 
level of NORAD and that of miR‐205 
in 20 matched tissues. Linear regression 
coefficients and statistical significance 
is indicated. Association of NORAD and 
miR‐205 with Ago2 in A357 (C) and WM35 
(D) cells. Cellular lysates from A357 and 
WM35 cells were used for RIP with Ago2 
antibody. NORAD and miR‐205 expression 
levels were detected using qRT‐PCR. The 
relative luciferase activities were inhibited 
in the A357 (E) and WM35 (F) cells co‐
transfected with wild‐type NORAD vector 
and pre‐miR‐205, and not with the mutant‐
type vector. Firefly luciferase activity was 
normalized to Renilla luciferase
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in A375 (Figure 3E) and WM35 (Figure 3F) cells reduced 
miR‐205‐mediated repression of luciferase activity. The 
data indicated the binding of miR‐205 to NORAD.
3.4 | MiR‐205 inhibits MM cell 
migration and invasion
To determine if miR‐205 can regulate MM cell migration and 
invasion, transwell assays were performed through the transfec-
tion of precursor of miR‐205 (pre‐miR‐205) or scramble con-
trol into A375 and WM35 cells (Figure 4A). Overexpression of 
miR‐205 induced the inhibition of migration compared to the 
scramble control (Figure 4B). The corresponding effect on cell 
invasion was found (Figure 4C) suggesting that miR‐205 can 
inhibit migration and invasion in MM cells.
3.5 | Downregulation of NORAD 
substantially reverses knockdown of miR‐205‐
induced migration and invasion
Based on the observed regulatory effect between NORAD 
and miR‐205, we further investigated whether NORAD 
mediated the inhibitory effects of miR‐205 knockdown in 
tumor migration and invasion. A375 and WM35 cells were 
transfected with anti‐miR‐205 or shNORAD alone, or co‐
transfected with both. The qRT‐PCR results revealed that 
knockdown of NORAD significantly reversed the downreg-
ulation of miR‐205 (Figure 5A). We further evaluated the 
regulatory effects of downregulated of NORAD, specifically 
whether the knockdown of miR‐205 affected cancer cell mi-
gration and invasion. The downregulation of NORAD largely 
reversed the inhibitory effect of the deletion of miR‐205 on 
cell migration and invasion (Figure 5B and C).
3.6 | Egl nine homolog 2 (EGLN2) is 
target of miR‐205 and downregulation of 
NORAD substantially reverses knockdown of 
miR‐205‐induced ER stress of MM cells
EGLN2 has a binding site for miR‐205. Moreover, the ex-
pression of EGLN2 in 40 cases metastasis MM tissues was 
negatively related with the miR‐205 level (Figure 6A). 
Interestingly, the stable knockdown of NORAD sup-
pressed the expression of EGLN2 in A375 and WM35 cells 
(P < 0.05; Figure 6B). In addition, the dual‐luciferase re-
porter assay revealed that the relative luciferase activity was 
reduced in A375 and WM35 cells transfected with wild‐type 
vector after overexpression of miR‐205, while the mut vector 
F I G U R E  4  MiR‐205 inhibits 
migration and invasion of malignant 
melanoma cells. (A) qPCR was performed 
to detect the expression of miR‐205 in 
A357 and WM35 cells after transfection 
with pre‐miR‐205. (B) The overexpression 
of miR‐205 inhibited the migration of 
A357 and WM35 cells. (C) miR‐205 
overexpression inhibited the invasion 
of A357 and WM35 cells. **P < 0.01, 
***P < 0.001 vs normal control (NC). 
Images were obtained at 100× magnification
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reversed this inhibitory effect (Figure 6C and D). The results 
demonstrated that EGLN2 is a target gene of miR‐205. The 
regulatory effects of NORAD on miR‐205 knockdown‐in-
duced downregulation of EGLN2 and ER‐related genes were 
measured by western blot assay. NORAD knockdown dra-
matically reversed the increased EGLN2 and ER‐related gene 
levels, including GRP78, CHOP, and eIF2α, which were sub-
stantially inhibited by miR‐205(Figure 6E). The results indi-
cated that NORAD can regulate migration, invasion, and ER 
stress of MM cells by targeting EGLN2 via miR‐205.
3.7 | Downregulation of NORAD mostly 
reverses knockdown of miR‐205‐induced tumor 
growth in nude mice
To investigate the effects of NORAD/miR‐205 axis in 
vivo, human melanoma A375 cells were subcutaneously 
inoculated into nude mice. The growth curve of each group 
(Figure 7A) revealed that the anti‐miR‐205 group of nude 
mice displayed a higher tumor volume than the negative 
control, Lv‐shNORAD, and anti‐miR‐205 + Lv‐shNO-
RAD groups (P < 0.05). After 35 days, the mice were sacri-
ficed and the tumors were removed (Figure 7B). The mean 
tumor volume was 2.093 ± 0.353 cm3 in the anti‐miR‐205 
group, which was higher than the blank vector group, 
shNORAD, and anti‐miR‐205 + Lv‐shNORAD groups 
(1.293 ± 0.353, 0.798 ± 0.123, and 1.193 ± 0.233 cm3, 
respectively) (Figure 7C). The anti‐miR‐205 group had 
higher average tumor weight than that in the blank vector, 
shNORAD, and anti‐miR‐205 + Lv‐shNORAD groups 
(Figure 7D). We validated the promoting effects of down-
regulated miR‐203 on human melanoma xenograft forma-
tion, while downregulation of NORAD mostly reversed 
these effects.
F I G U R E  5  Downregulation of 
NORAD almost completely reverses 
knockdown of miR‐205‐induced migration 
and invasion of malignant melanoma cells. 
(A) qPCR was performed to detect the 
expression of miR‐205 in A357 and WM35 
cells after transfection with anti‐miR‐205 
or Lv‐shNORAD, or with both of them. (B) 
The downregulation of miR‐205 reversed 
NORAD knockdown‐mediated inhibition of 
the migration of A357 and WM35 cells. (C) 
The downregulation of miR‐205 reversed 
NORAD knockdown‐mediated inhibition 
of the invasion of A357 and WM35 cells. 
**P < 0.01, ***P < 0.001 vs normal 
control (NC). Images were obtained at 100× 
magnification
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4 |  DISCUSSION
LncRNAs are regulators of various biological processes and 
they play a critical role in various cancers, including MM. 
NORAD was identified as a novel lncRNA in response to 
DNA damage and has a role in the progression of cancer.13 
However, it is unclear whether NORAD can regulate the mi-
gration and invasion of melanoma cells.
We observed high levels of NORAD in melanoma tissues 
and human malignant melanoma cells, particularly in meta-
static MM. NORAD knockdown significantly repressed MM 
cell migration and invasion. NORAD acts as a molecular 
sponge in regulating miR‐205. Furthermore, EGLN2 encodes 
prolyl hydroxylase 2, which is a key regulator of ER stress and 
the target of miR‐205. Knockdown of NORAD increased the 
expression of miR‐205 and subsequently decreased EGLN2 
expression. In addition, knockdown of miR‐205 induced an 
promotion of migration, invasion, and ER stress in MM cells.
Severe ER stress induced cell death, invasion and al-
terations of morphology by decreasing the expression of 
unfolded protein response target genes, including CHOP, 
GRP78, and EF2a.14 ER stress induces epithelial‐mesen-
chymal transition in lung cancer cells and participates in 
the progression of metastasis.15,16 In addition, ER stress‐in-
duced invasion and migration of breast cancer cells can be 
suppressed by downregulation of heparanase.17 Our data 
demonstrated that silencing of NORAD can inhibit ER stress. 
Although the present study did not provide direct evidence 
whether changes in ER stress were required for the promotion 
F I G U R E  6  EGLN2 is a direct target 
of miR‐205 and downregulation of NORAD 
almost completely reverses knockdown of 
miR‐205‐induced endopl‐asmic reticulum 
stress of malignant melanoma cells. (A) 
Correlation between the expression level of 
EGLN2 and that of miR‐205 in 20 matched 
tissues. Linear regression coefficients and 
statistical significance is indicated. (B) 
Western blot analysis for EGLN2 after 
transfection with Lv‐shNORAD. β‐actin 
was used a loading control. **P < 0.01, 
***P < 0.001 vs normal control (NC) (C, 
D) The relative luciferase activities were 
inhibited in the A357 and WM35 cells 
co‐transfected with wild‐type EGLN2 
3′‐UTR vector and pre‐miR‐205, and 
not with the mutant‐type vector. Firefly 
luciferase activity was normalized to Renilla 
luciferase. **P < 0.01, ***P < 0.001 vs 
normal control (NC) (E) Western blot 
analysis for EGLN2, CHOP, GRP78, 
eEIF2a, and p‐eEIF2a after treatment. β‐
actin was used a loading control
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of invasion and migration of MM cells caused by NORAD, 
further investigating the role of NORAD and ER stress in cell 
invasion and migration may provide an novel thought to MM 
therapies.
The “competing endogenous RNAs” theory posits a novel 
mechanism of between lncRNA and miRNA.18 We found that 
miR‐205 may be a target of NORAD by bioinformatic pre-
diction based on complementary sequences. RIP and lucif-
erase reporter assay analyses demonstrated that miR‐205 has 
direct binding sites on NORAD. The function of miR‐205 as 
a tumor suppressor was firstly found in breast cancer,19 and 
then on, downregulated of miR‐205 and the tumor suppressor 
role of in the occurrence and development of several types 
of cancer such as cervical cancer,20 colorectal cancer,21 and 
bladder cancer22 has been established. However, MiRNAs 
can target various genes and single gene can be modulated by 
many MiRNAs, therefore, the biological outcomes of miRNA 
activation may change with cell content and stimulus, which 
provides potential explanations for the complicated and con-
troversial functions of miRNA. MiR‐205 is a “double‐edged 
sword” in cancer, some studies described miR‐205 is also up-
regulated in some cancers, such as ovarian cancer and head 
and neck cancers.23,24According to our observations and 
other studies, we confirmed that miR‐205 is downregulated 
in MM.25-27 Another study also described the downregulation 
of miR‐205 in human MM tissues and cells,28 which heralds 
a poor prognosis for melanoma patients.29 Upregulation of 
MiR‐205 also restrained growth, migration, and invasion 
of MM cells through the targeting of erbb3, E2F1, and the 
zinc‐finger E‐box binding homeobox2.28,30-33 These observa-
tions are identical to our observations that the up‐regulation 
of miR‐205 can inhibit MM cell migration and invasion, and 
that EGLN2 is a target gene of miR‐205.
EGLN2 is believed to be the major regulator of the hypoxia 
response, participating in diverse biological processes in-
cluding cell invasion and cell death.34 EGLN2 is an invasion‐
associated gene. It is abundantly expressed in highly invasive 
lung cancer cells and has been recognized as a prognostic fac-
tor for non‐small cell lung cancer. Moreover, miR‐205 could 
bind to the EGLN2 3′‐UTR and dampen transcription level 
of EGLN2, which regulates the level of intracellular reactive 
oxygen species, cell invasion, and ER stress.35
In our study, stable knockdown of NORAD dampened 
expression of EGLN2 in A375 and WM35 cells, and the 
regulatory effects of NORAD on the expression of EGLN2 
and ER‐related genes, for example,GRP78, CHOP, and 
eIF2α were largely reversed by miR‐205. WM35 cells are 
poorly tumorigenic and can even be non‐tumorigenic in nude 
mice. Thus, only A375 cells were selected to further con-
firm the effect of the NORAD/miR‐205 axis. In the exper-
iment involving nude mice, the downregulation of miR‐205 
promoted growth of melanoma xenografts, while the knock-
down of NORAD almost completely reversed the promo-
tion of growth. Thus, it is reasonable to conclude that the 
F I G U R E  7  Knockdown of NORAD 
suppresses tumor growth in nude mice. (A) 
Growth curve of nude mice with different 
levels of miR‐33a‐5p expression. Day 0 
means the day of injection of tumor cells. 
(B) Representative images of nude mice and 
subcutaneous tumors at day 42. Volume (C) 
and (D) weight of A375 xenografts in each 
group. *P < 0.05, **P < 0.01, ***P < 0.001 
vs normal control (NC)
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NORAD/miR‐205 axis inhibits the migration and invasion 
of MM cells, and it may caused by the induction of ER stress.
In conclusion, the overexpression of NORAD is associ-
ated with metastasis of MM cells. NORAD interacts with 
miR‐205 and acts as an oncogene, which enhances the malig-
nancy of MM cells. The present data reveal the participation 
of NORAD in the tumorigenesis of MM cells, and may indi-
cate a novel therapeutic target.
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